Advances in the Early Diagnosis of Hepatocellular Carcinoma

Overview

Journal Genes Dis

Date 2020 Sep 5

PMID 32884985

Citations 170

Authors

Weiyi Wang

Chao Wei

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers globally. In contrast to the declining death rates observed for all other common cancers such as breast, lung, and prostate cancers, the death rates for HCC continue to increase by ~2-3% per year because HCC is frequently diagnosed late and there is no curative therapy for an advanced HCC. The early diagnosis of HCC is truly a big challenge. Over the past years, the early diagnosis of HCC has relied on surveillance with ultrasonography (US) and serological assessments of alpha-fetoprotein (AFP). However, the specificity and sensitivity of US/AFP is not satisfactory enough to detect early onset HCC. Recent technological advancements offer hope for early HCC diagnosis. Herein, we review the progress made in HCC diagnostics, with a focus on emerging imaging techniques and biomarkers for early disease diagnosis.

Citing Articles

Serum-biomarker-based population screening model for hepatocellular carcinoma.

Liao W, Lin W, He Z, Feng C, Liu Y, Wang Z iScience. 2025; 28(3):111981.

PMID: 40060905 PMC: 11889663. DOI: 10.1016/j.isci.2025.111981.

Uncovering immune cell heterogeneity in hepatocellular carcinoma by combining single-cell RNA sequencing with T-cell receptor sequencing.

Gu X, Gu S, Chen Z, Tong J, Li X, Dong H World J Hepatol. 2025; 17(2):99046.

PMID: 40027555 PMC: 11866147. DOI: 10.4254/wjh.v17.i2.99046.

Research Progress on Contrast-Enhanced Ultrasound (CEUS) Assisted Diagnosis and Treatment in Liver-Related Diseases.

Ying X, Dong S, Zhao Y, Chen Z, Jiang J, Shi H Int J Med Sci. 2025; 22(5):1092-1108.

PMID: 40027182 PMC: 11866529. DOI: 10.7150/ijms.101789.

Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma.

Kim D, Kim E, Lee J, Kim M, Kim B, Kim S Cancers (Basel). 2025; 17(4).

PMID: 40002160 PMC: 11853259. DOI: 10.3390/cancers17040566.

Application of Indirect ELISA and PCR Techniques for Detecting of Hepatocellular Carcinoma using Des-gamma Carboxyprothrombin, Alpha-fetoprotein, and Thioredoxin Biomarkers.

Huy D, Khai N, Thinh T, Linh B, Minh N, Thuy V Mol Biotechnol. 2025; .

PMID: 39998774 DOI: 10.1007/s12033-025-01401-z.

References

Gupta S, Bent S, Kohlwes J . Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003; 139(1):46-50. DOI: 10.7326/0003-4819-139-1-200307010-00012. View

Li X, Li C, Wang R, Ren J, Yang J, Zhang Y . Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis. PLoS One. 2015; 10(12):e0144247. PMC: 4668097. DOI: 10.1371/journal.pone.0144247. View

Huang A, Zhang X, Zhou S, Cao Y, Huang X, Fan J . Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer. 2016; 7(13):1907-1914. PMC: 5039376. DOI: 10.7150/jca.15823. View

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

Tahon A, El-Ghanam M, Zaky S, Emran T, Bersy A, El-Raey F . Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Cancer. 2018; 50(3):434-441. DOI: 10.1007/s12029-018-0095-2. View

Yang J, Addissie B, Mara K, Harmsen W, Dai J, Zhang N . GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2018; 28(3):531-538. PMC: 6401221. DOI: 10.1158/1055-9965.EPI-18-0281. View

Zheng Z, Pang C, Yang Y, Duan Q, Zhang J, Liu W . Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Int Med Res. 2017; 46(1):348-356. PMC: 6011314. DOI: 10.1177/0300060517726441. View

Xie D, Ren Z, Zhou J, Fan J, Gao Q . Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2018; 6(6):387-396. PMC: 5756765. DOI: 10.21037/hbsn.2017.11.01. View

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

10.

Banales J, Inarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, Munoz-Bellvis L . Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology. 2018; 70(2):547-562. PMC: 6767196. DOI: 10.1002/hep.30319. View

11.

Claudon M, Dietrich C, Choi B, Cosgrove D, Kudo M, Nolsoe C . Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2012; 39(2):187-210. DOI: 10.1016/j.ultrasmedbio.2012.09.002. View

12.

Liu J, Zuo X, Wang S . Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2015; 19(19):3655-73. View

13.

Rao C, Asch A, Yamada H . Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2016; 38(1):2-11. PMC: 5219050. DOI: 10.1093/carcin/bgw118. View

14.

Peng C, Ye Y, Wang Z, Guan L, Bao S, Li B . Circulating microRNAs for the diagnosis of hepatocellular carcinoma. Dig Liver Dis. 2019; 51(5):621-631. DOI: 10.1016/j.dld.2018.12.011. View

15.

Singal A, Pillai A, Tiro J . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11(4):e1001624. PMC: 3972088. DOI: 10.1371/journal.pmed.1001624. View

16.

Sun B, Huang Z, Wang B, Yu Y, Lin S, Luo L . Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis. Med Sci Monit. 2017; 23:850-855. PMC: 5325041. DOI: 10.12659/msm.899198. View

17.

Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O . Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011; 29(3):339-64. DOI: 10.1159/000327577. View

18.

Kirk G, Lesi O, Mendy M, Szymanska K, Whittle H, Goedert J . 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005; 24(38):5858-67. DOI: 10.1038/sj.onc.1208732. View

19.

Lee S, Lee H, Kim J, Lee H, Jang J, Kang G . Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003; 163(4):1371-8. PMC: 1868296. DOI: 10.1016/S0002-9440(10)63495-5. View

20.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View